Axon Enterprise AXON
Industrials · Aerospace & Defense · Synthos Deep Dive · 2026-07-03
The Overview
Axon makes the TASER stun guns and body cameras that most American police departments use — and, more importantly, the cloud software that stores and manages all the video and evidence those devices capture. Once a police department is on Axon's system, it almost never leaves (they keep 125 cents of every subscription dollar year to year). That software business is the real prize, and newer products — anti-drone systems and AI tools that write police reports — are growing explosively.
The catch: the stock is very expensive. Investors are already paying a huge premium price that assumes Axon keeps growing about 30% a year for years. The company is good enough that it might — but if it stumbles even a little, the stock can fall a lot (it's already down about a third from its high). Our verdict is Watch: great company, wrong price today. Wait for a dip.
Here's what our three scores mean in everyday terms:
- Downside Risk 8/10 (high). Not because the company is fragile — it's because the stock is priced so richly and moves so much that the downside if anything goes wrong is large.
- Growth Quality 8/10 (excellent). A top-tier, fast-growing, super-sticky business.
- Exponential Potential 7/10 (high). It's still growing fast and barely slowing down, with big new markets ahead — the reason to keep watching it closely.
The one big worry: you're paying a top-dollar price. If growth slows even to "merely good," the stock could drop sharply because the high price has to come down to earth.
Putting a number on it: our fair-value estimate is $617 against a current price of $600.73 — real upside if our numbers are right.
Our summary metrics
Fortress-lite (net-debt/EBITDA 3.5×) but 56× FY27E EPS, beta 1.42, RSI 80, and a −31% drawdown already this cycle.
~30% durable revenue CAGR, 59% gross margin, ARR $1.5B +35%, 125% net retention — quality is high; GAAP EPS is SBC-muddied.
Growth barely decelerating (32%→29%) with counter-drone/AI +300–700% and a large room-to-run vs a $48B cap — genuine, but priced for it.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, We don’t publish a reverse-DCF cross-check for pre-profit companies — negative or missing earnings break that math — so take this number on our modeling alone.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Growth barely decelerating (32%→29%) with counter-drone/AI +300–700% and a large room-to-run vs a $48B cap — genuine, but priced for it.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $652 (high $820 / low $440; 17 Buy · 4 Hold · 0 Sell) — context, not our anchor |
| Valuation | 231× trailing GAAP EPS · 78× FY26E · 56× FY27E · 43× FY28E (non-GAAP) · EV/S 16.6× · EV/EBITDA 128× (GAAP, SBC-depressed) |
| Technicals | Uptrend but hot — $597, −31% off 52-wk high, above 50/200-DMA, RSI 80 (overbought), −23% 12-mo (SPY +21%) |
| Conviction | Low — 1 net-bullish voice, 11 claims (single source, dated 2024-10). This is a fundamentals/quant-driven call, not a panel-backed one |
| Position sizing | Watch / starter-only, ≤1–2% if entered; wait for a pullback off RSI 80 |
What the experts actually said 11 traceable claims on AXON · showing the highest-conviction voices
“Axon's taser monopoly seeds a flywheel into body cameras and evidence software, shifting to 95% subscription revenue with expanding margins.”
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $600.73, 8% above the 50-day average ($557), 19% above the 200-day average ($506) — an uptrend. 23% below the 52-week high of $782, 74% above the 52-week low of $346.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $600.73 is currently inside the band (band $554–$655).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 53.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 3.91, negative momentum.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = AXON · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Axon Enterprise (NASDAQ: AXON), founded 1993 in Scottsdale AZ as TASER International (rebranded 2017), is a public-safety technology company. Its classic business is the TASER conducted-energy weapon (a near-monopoly with US police). On top of that hardware base it has built a cloud software and sensors ecosystem: body cameras (Axon Body 4), in-car/fleet video, the Axon Evidence digital-evidence-management cloud, real-time operations, the Dedrone counter-drone line, and a fast-growing AI suite (Draft One report-writing, Axon Assistant, Axon Vision/Guardian). Fiscal year ends December 31. CEO and founder: Patrick W. Smith.
Revenue mix (FY2025, from filings):
- By product/segment: Software & Sensors segment $1.20B, TASER (X2 line) $0.91B, Axon Body $0.40B, Platform Solutions $0.27B — the software+sensors side is now the majority of revenue and the growth engine.
- By geography: United States $2.31B (83%) · Non-US $0.47B (17%). Heavily US-concentrated — a domestic-institution strength but an international-runway opportunity (management flags growing international, federal, corrections and enterprise adoption).
The strategic story is a hardware-to-software flywheel: TASER/body-camera hardware seeds a fleet that pulls agencies onto multi-year cloud subscriptions, which now compound at ARR $1.5B (+35% YoY) with net revenue retention of 125% and roughly 95% subscription-like revenue — plus new S-curves in counter-drone (+300% YoY) and AI (+700% YoY).
2. The expert thesis — why the (thin) panel is bullish (traceable)
Honest breadth disclosure: this is a thin-coverage name. The Synthos KB holds 11 traceable claims from a single net-bullish voice — no broad panel, and the most recent claim is dated 2024-10-24 (nine months stale). This verdict is therefore fundamentals- and quant-driven, with the expert claim used only as corroboration, not as the anchor.
- The one voice (high conviction, high skill): Business Breakdowns (
business_breakdowns-EuNEJpkla1U:f4ee23af8e, bullish, conviction 85, skill 1.0): "Axon's TASER monopoly seeds a flywheel into body cameras and evidence software, shifting to 95% subscription revenue with expanding margins." That thesis has aged well — the FY25/Q1'26 numbers (ARR $1.5B +35%, NRR 125%, Software Services +35%) are exactly the flywheel playing out.
Honest composite note. With breadth of 1 and a nine-month-old claim, we do not carry panel conviction here. The bullish direction is real but under-corroborated in our KB; the fundamentals and quant screen carry the call. Do not read the +85 conviction as a broad consensus — it is one (good) source.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (higher = riskier) | 8 · High | Not balance-sheet fragility (cash+ST inv $1.7B, current ratio 2.3×) but valuation + volatility: 56× FY27E EPS, 128× GAAP EV/EBITDA, beta 1.42, RSI 80, and a −31% drawdown already this cycle. Net-debt/EBITDA screens 3.5× only because GAAP EBITDA is SBC-depressed. |
| Growth Quality | 8 · Very High | ~30% durable revenue CAGR, 59% gross margin, ARR $1.5B (+35%), 125% net retention, nine straight quarters of 30%+ growth. Knock: GAAP earnings are muddied by heavy stock comp ($634M FY25) and one-off items. |
| Exponential Potential | 7 · High | Revenue growth barely decelerates (32%→29%→29% FY26–28E); counter-drone +300% and AI +700% are new S-curves; $48B cap vs a large public-safety+enterprise TAM = real room. Capped from "9" only because the market already prices the exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Counter-drone/AI keep compounding 100%+; NRR stays ≥120%; international & enterprise open a second leg. FY27E EPS beats to ~$12.5 (vs $10.64 cons); market keeps paying ~60× for durable 30% growth. | ~$750 (+26%) |
| Base (our anchor) | Estimates roughly hit — FY27E non-GAAP EPS $10.64; a durable 30% compounder with 59% GM and 125% NRR earns a still-premium but compressing ~58×. | ~$617 (+3%) |
| Bear | Growth decelerates toward 20%, an AI/counter-drone S-curve disappoints, or the high-beta name de-rates in a risk-off tape. FY27E EPS misses to ~$8.5; multiple compresses to ~40×. | ~$340 (−43%) |
Synthos fair value = the base case, ~$617 (+3%), with the full $340–$750 span as the honest range. Note the asymmetry: the bear ($340, −43%) is deeper than the bull ($750, +26%) is high — that skew is exactly why the verdict is Watch, not Buy, despite an excellent business. Our base sits just below the Street's $652 consensus. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). AXON is a rare case that still leans exponential — the reason it scores 7, not the 5 a decelerating mega-cap would earn:
- Forward growth: revenue CAGR FY25→FY28E ~29.8% ($2.78B → $6.08B); non-GAAP EPS CAGR FY26→FY28E ~34% ($7.69 → $13.89) as software mix lifts margins.
- Acceleration (the 2nd derivative) is only mildly negative: revenue growth +33.5% (FY25 actual) → +31.6% (FY26E) → +29.3% (FY27E) → +28.6% (FY28E). This is barely decelerating — extraordinary at this scale — and the product-level acceleration is positive: Platform Solutions +95% YoY, counter-drone +300%, AI +700% (Q1'26). New S-curves are still igniting.
- Room to run: at $48B market cap against a public-safety + emerging enterprise/corrections/federal/international TAM that management is actively expanding (Draft One into healthcare, Dedrone into datacenters/critical infrastructure), the room-to-run is real — a 3× from here (~$145B) is not law-of-large-numbers-blocked the way a $1T name would be.
- Reinvestment runway: heavy R&D (22% of revenue) and SBC-funded talent, plus M&A (Fusus, Dedrone) — reinvestment is aggressive and, so far, productive (each acquisition is inside the flywheel).
Exponential Potential: High. This is one of the few S&P 500 names that genuinely still compounds like a growth company rather than a mature compounder. The catch is entirely on price, not on the growth engine — which is why it lands in Watch.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $2.78B, +33.5% (FY24 $2.08B, +33% on FY23 $1.56B). Nine consecutive quarters of 30%+ growth — remarkably consistent.
- Quarterly trajectory: Q1'25 $604M → Q2 $669M → Q3 $711M → Q4 $797M → Q1'26 $807M (+34% YoY). Steady sequential build.
- ARR / retention: ARR $1.5B, +35% YoY; net revenue retention 125%; Software Services $355M (+35%) in Q1'26. This is the durable, high-quality core.
- Margins: gross 59.3% TTM (software-led and rising), but GAAP operating income is thin/negative because of heavy stock-based comp ($634M FY25) and non-operating items. Management's non-GAAP frame: Q1'26 adj. EBITDA $202M (~25% margin), FY26 guided ~25.5%.
- Earnings quality caveat (important): GAAP EPS is noisy — FY25 GAAP EPS $1.60, TTM P/E 231× — distorted by SBC, tax items, and mark-to-market on strategic investments. The non-GAAP path (FY26E $7.69 → FY27E $10.64 → FY28E $13.89) is the honest earnings lens, and even that is richly valued. SBC at ~21% of revenue is a real, ongoing shareholder cost — not a one-time add-back.
- Cash flow: FY25 operating CF $211M, capex −$136M, FCF just $75M (compressed by working-capital build and M&A); management guides FY26 to operating CF >$600M and FCF ~$450M — a large step-up to watch. FCF yield is currently negligible (<0.1%).
- Balance sheet: cash + ST investments $1.71B, total debt $1.91B, net debt ~$709M; current ratio 2.3×. Comfortable, though the 2025 convert/debt raise ($1.14B) added leverage.
6. Valuation — priced in or room?
There is no way to call AXON cheap. On trailing GAAP it is 231× EPS, 16.6× sales, 128× EV/EBITDA (the last two inflated by SBC-depressed profit). The bull's defense is the non-GAAP forward path: 78× FY26E → 56× FY27E → 43× FY28E. The multiple compresses fast if the ~30% growth holds — but even FY28E's 43× is a premium-growth multiple, so the stock is priced for continued 30% execution with little margin for error. A durable 30% grower arguably deserves a 40–60× multiple; the problem is that at $597 you're already paying near the top of that band, so your return comes almost entirely from earnings growth, not re-rating — and any deceleration re-rates you down. Street targets (context): consensus $652, high $820, low $440 — our $617 base FV sits just below consensus because we haircut for the RSI-80 entry and the asymmetric downside. Not a value buy; a great-business-at-a-full-price that we'd rather own cheaper.
7. Technicals (from the tech block)
- Trend: up but hot. $597 sits above the 50-DMA ($434) and 200-DMA ($533) — a name that sold off and is rallying back hard.
- Location: −31% off the 52-week high ($871) yet +73% off the 52-week low ($346) — this stock has already had a violent round-trip this cycle (max drawdown −31%). Volatility is a feature here, not a bug.
- Momentum: RSI(14) 80 — clearly overbought (>70). MACD +33 (positive). The +41% 3-month rip has stretched the entry; this is a wait-for-a-pullback setup, not a chase.
- Relative strength: AXON −23% 12-mo vs SPY +21% and QQQ +30% — a full-year laggard — but +41% 3-mo vs SPY +14% / QQQ +22%, i.e. sharp recent leadership off the lows. Mixed: long-term underperformer staging a strong short-term recovery.
- Read: technicals say don't chase here. RSI 80 after a +41% quarter argues for patience; a cool-off toward the 200-DMA (~$533) or the rising 50-DMA would be a materially lower-risk entry. This reinforces the Watch verdict.
8. Moat & competitive position
Axon's moat is a rare stack: (1) a near-monopoly in TASER (conducted-energy weapons) that seeds the ecosystem; (2) switching costs — once an agency's evidence lives in Axon Evidence and its workflows run on the platform, migration is painful, which is why net revenue retention is 125%; (3) data + AI compounding — the "Axon Gravity" vision to be the largest repository of AI-enhanced public-safety data is a data-network-effect play; (4) regulatory/procurement lock-in — CJIS-compliant, multi-year government contracts. The competitive frame is fragmented: body-cam/DEMS rivals (Motorola Solutions/WatchGuard, Utility), counter-drone specialists, and internal-build risk — but none match Axon's integrated flywheel. Threats: public-controversy/liability around use-of-force and AI surveillance, procurement-cycle lumpiness, and any misstep on facial-recognition/privacy politics.
Peer set (FMP-listed, market cap): these are industrial/defense comps rather than true business-model peers — Cummins $91B, Quanta Services $100B, TransDigm $75B, FedEx $75B, Canadian National $74B, United Rentals $69B, PACCAR $63B, L3Harris $56B, HEICO $50B. AXON commands the highest growth and richest multiple in this group by a wide margin; the truer comps (Motorola Solutions, vertical SaaS) aren't in the FMP peer list.
9. Management, capital allocation & guidance
- Capital allocation: growth-first — heavy R&D (22% of revenue), acquisitive (Fusus, Dedrone), no dividend, no buyback. Funded partly by a 2025 debt/convert raise (~$1.14B). Appropriate for a 30% grower, but SBC (~21% of revenue) is a persistent dilution/expense that shareholders bear.
- Insider activity: founder-CEO Patrick Smith sold 10,000 shares at ~$500 on 2026-06-29 (still holds ~3.05M); President Joshua Isner made a cluster of small Rule-10b5-1 sales in early June at ~$481–488. These read as routine/programmatic diversification, not an alarm — but note insiders were selling into the low-$500s, below today's $597.
- Management's own guidance (the earnings-call track — half-weighted, self-interested): from the Q1'26 earnings release (SEC 8-K, filed 2026-05-06), management raised full-year 2026 revenue guidance to +30–32% growth (up from 27–30%), maintains an ~25.5% adjusted-EBITDA margin, and guides operating cash flow >$600M and FCF ~$450M for FY26. They cite ARR $1.5B (+35%), NRR 125%, AI product revenue +700% YoY and counter-drone +300% YoY. This is management's own book — treat the raised outlook as a genuine positive signal but half-weight it; the FY26 FCF step-up to ~$450M (from $75M FY25) is the specific number to hold them to.
10. Catalysts & what to watch
- Next earnings: 2026-08-03 (Q2'26; Street EPS $1.83, revenue ~$876M). Watch: ARR growth, net revenue retention (is it still ≥120%?), and whether the raised FY26 revenue guide holds.
- FCF inflection: progress toward the guided >$600M operating CF / ~$450M FCF — the single most important tell that profits are becoming cash.
- New S-curves: counter-drone (Dedrone) and AI (Axon Vision GA in early Q4'26, Guardian, Assistant) adoption — the exponential legs.
- International / enterprise / federal expansion: the second growth leg beyond US police.
- Regulatory/controversy: any use-of-force liability, AI-surveillance or privacy backlash that could dent procurement.
Thesis tripwires (what would change the call): net revenue retention slipping below ~115%; two quarters of sub-25% revenue growth; the FY26 FCF guide missed materially; or a governance/controversy shock.
11. Key risks
- Valuation / de-rating (the dominant risk): 56× FY27E EPS and 128× GAAP EV/EBITDA leave no margin for error; a growth wobble compresses the multiple hard (bear case −43%).
- Stock-based comp: ~21% of revenue in SBC is a real, ongoing cost that flatters non-GAAP metrics and dilutes shareholders.
- Volatility / beta 1.42: the stock has already round-tripped −31% this cycle; RSI 80 entry is stretched.
- Concentration & procurement lumpiness: 83% US revenue, government budget cycles, and large-contract timing can create quarter-to-quarter noise.
- Thin conviction / stale coverage: only 1 KB voice, last claim 2024-10 — we lack panel corroboration, so the call rests on fundamentals/quant.
- Controversy/regulatory: use-of-force liability and AI-surveillance/privacy politics are a live reputational and procurement risk for this specific business.
12. Verdict, position sizing & monitoring
Watch. Axon is a genuinely elite business — a TASER monopoly that flywheeled into 95%-sticky evidence software (ARR $1.5B +35%, NRR 125%), with counter-drone and AI now inflecting at 300–700% growth and management raising FY26 guidance. On business quality alone it would be a Buy. But the verdict is Watch, not Buy, for two honest reasons: (1) price — at 56× FY27E non-GAAP EPS the base case is only +3% to fair value while the bear is −43%, an unattractive skew; and (2) entry — RSI 80 after a +41% quarter is a chase. We want this business; we want it cheaper.
- Sizing: if entered at all, starter-only, ≤1–2%, and scale in on weakness toward the 200-DMA (~$533) or lower. Do not chase RSI 80.
- Monitoring: re-underwrite on the §10 tripwires; re-score each earnings print. A pullback to the low-$500s (where insiders were selling) with NRR intact would flip this toward Buy — Tactical.
- Single biggest risk: multiple compression — the whole downside is that a durable 30% grower priced at 56× de-rates on any growth stumble.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $597.04.
Provenance & disclosures
- Traceability: 11 KB claims, breadth 1, top skill 1.0 (Business Breakdowns), last claim 2024-10-24 — reconciled to a real
claim_id(business_breakdowns-EuNEJpkla1U:f4ee23af8e). Thin coverage is disclosed, not hidden; this is a fundamentals/quant-driven call. Fabricated conviction is structurally impossible (claim-ID reconciliation). - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · expert claim through 2024-10-24. Forward figures are analyst consensus (FMP), labeled as estimates. GAAP vs non-GAAP earnings are distinguished explicitly (§5).
- Management caveat: the raised FY26 guidance (§9) is management's own SEC 8-K earnings-release outlook — self-interested, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").